Comparative evaluation of Anyplex II HPV28 and Allplex HPV28 molecular assays for human papillomavirus detection and genotyping in anogenital cancer screening
Open Access
- 29 May 2024
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (6) , e29649
Abstract
Persistent infection with high‐risk human papillomavirus (HPV) is recognized as the main cause for the development of anogenital cancers. This study prospectively evaluated the diagnostic performance of the novel Allplex‐HPV28 assay with the Anyplex‐II‐HPV28 to detect and genotype HPV in 234 consecutive swabs and 32 biopsies of the anogenital tract from 265 patients with atypical findings in cytomorphological screening. Agreement in HPV‐DNA detection between the Anyplex‐II and Allplex‐HPV28 assays was 99%. There was a notable diversity in the HPV‐virome, with the most prevalent high‐risk HPV types being 16, 53, 66, and 68. The agreement rates for detecting these genotypes exceeded 93% between the Anyplex‐II and Allplex‐HPV28 assays. Discrepancies in test results were solely noted for Anyplex‐II‐HPV28 results with a low signal intensity of “+”, and for Allplex‐HPV28 results with cycle thresholds of ≥36. The semi‐quantitative analysis of HPV‐DNA loads showed significant agreement between the Anyplex‐II‐HPV28 and Allplex‐HPV28 assays ( p < 0.001). Furthermore, HPV‐DNA detection rates and mean HPV‐DNA loads significantly correlated with the grade of abnormal changes identified in cytopathological assessment, being highest in cases of HSIL, condyloma accuminatum, and squamous cell carcinoma. Overall agreement rates for detecting specific HPV‐types among the Anyplex‐II and Allplex‐HPV28 assays exceeded 99.5% in cases of atypical squamous cells, condyloma accuminatum, and squamous cell carcinoma. The novel Allplex‐HPV28 assay shows good diagnostic performance in detecting and genotyping HPV commonly associated with anogenital cancers. Consequently, this assay could offer substantial potential for incorporation into future molecular screening programs for anogenital cancers in clinical settings.Keywords
This publication has 43 references indexed in Scilit:
- Amplicon size and non‐encapsidated DNA fragments define plasma cytomegalovirus DNA loads by automated nucleic acid testing platforms: A marker of viral cytopathology?Journal of Medical Virology, 2023
- Impact of nucleic acid extraction procedures on human papillomavirus (HPV) detection and genotypingJournal of Medical Virology, 2023
- Epidemiology and precision of SARS‐CoV‐2 detection following lockdown and relaxation measuresJournal of Medical Virology, 2020
- Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plansClinical Microbiology and Infection, 2020
- Initial results of population based cervical cancer screening program using HPV testing in one million Turkish womenInternational Journal of Cancer, 2017
- Anyplex II HPV28 detection and Anyplex II HPV HR detection assays are highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalitiesEuropean Journal of Clinical Microbiology & Infectious Diseases, 2016
- Association between human papillomavirus (HPV) 16, HPV18, and other HR‐HPV viral load and the histological classification of cervical lesions: Results from a large‐scale cross‐sectional studyJournal of Medical Virology, 2016
- The Burden of HPV-Associated Anogenital CancersCurrent Oncology Reports, 2014
- Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and olderInternational Journal of Cancer, 2008
- Persistence and load of high‐risk HPV are predictors for development of high‐grade cervical lesions: A longitudinal French cohort studyInternational Journal of Cancer, 2003